NCT03204487View on ClinicalTrials.gov

A Study on the Effect of Changing From Preserved Prostaglandin Formulations to Preservative Free Tafluprost on Tear Film Thickness

PHASE4CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 10, 2016

Primary Completion Date

April 25, 2017

Study Completion Date

June 30, 2017

Conditions
Glaucoma, Open-AngleOcular Hypertension
Interventions
DRUG

Tafluprost 15µg/ml

Tafluprost 15µg/ml (Saflutan® 15 microgram/ml Augentropfen im Einzeldosisbehältnis, Merck Sharp \& Dohme, Wien)

Trial Locations (1)

1080

Ordination Dr. Hommer, Vienna

All Listed Sponsors
lead

Ordination Dr. Hommer

OTHER

NCT03204487 - A Study on the Effect of Changing From Preserved Prostaglandin Formulations to Preservative Free Tafluprost on Tear Film Thickness | Biotech Hunter | Biotech Hunter